Cost-effective market access strategy for medical technologies in Europe
A holistic approach to reimbursement strategies trusted by global market leaders and SMEs
Recent news and posts
New procedure and diagnostic codes added to the private reimbursement schedule in England
On October 10, 2024, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclatures for private payers in England, published Bulletins 198 and 094 with changes to be implemented no later than December 5, 2024.
Fifty-two new procedure codes related to ENT, gastrointestinal, men’s health, urology, neurology and neurosurgery, gynecology, orthopedics, robotic surgery, and surgical procedures areas were introduced. Some examples of newly added codes are provided below:
- GA403 Laser assisted voice adjustment for gender affirmation;
- GA510 Metoidioplasty +/- urethral reconstruction (+/- scrotoplasty) (including cystoscopy) for gender affirmation;
- GA304 Augmentation mammoplasty for gender affirmation +/- implant, +/- fat transfer – unilateral;
- GA100 Cycle of ovarian stimulation and egg recovery with oocyte cryopreservation for gender affirmation;
- G6083 Robotic assisted small bowel resection +/- stoma.
Two new diagnostic codes were added in diagnostic nomenclature, including 9007G “Assessment of recurrence risk in bladder cancer by circulating tumour DNA profiling”.
See the full details here.
This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.